title: Protective effect of orally administered carnosine on bleomycin-induced lung injury.
abstract: Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and L-histidine. It acts as a free radical scavenger and possesses antioxidant properties. Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), IL-1, and TNF-alpha in different experimental settings. In the present study, we investigated the efficacy of carnosine on the animal model of bleomycin-induced lung injury. Mice were subjected to intratracheal administration of bleomycin and were assigned to receive carnosine daily by an oral bolus of 150 mg/kg. One week after fibrosis induction, bronchoalveolar lavage (BAL) cell counts and TGF-beta levels, lung histology, and immunohistochemical analyses for myeloperoxidase, TGF-beta, inducible nitric oxide synthase, nitrotyrosine, and poly(ADP-ribose) polymerase were performed. Finally, apoptosis was quantified by terminal deoxynucleotidyltransferase-mediated UTP end-labeling assay. After bleomycin administration, carnosine-treated mice exhibited a reduced degree of lung damage and inflammation compared with wild-type mice, as shown by the reduction of 1) body weight, 2) mortality rate, 3) lung infiltration by neutrophils (myeloperoxidase activity and BAL total and differential cell counts), 4) lung edema, 5) histological evidence of lung injury and collagen deposition, 6) lung myeloperoxidase, TGF-beta, inducible nitric oxide synthase, nitrotyrosine, and poly(ADP-ribose) polymerase immunostaining, 7) BAL TGF-beta levels, and 8) apoptosis. Our results indicate that orally administered carnosine is able to prevent bleomycin-induced lung injury likely through its direct antioxidant properties. Carnosine is already available for human use. It might prove useful as an add-on therapy for the treatment of fibrotic disorders of the lung where oxidative stress plays a role, such as for idiopathic pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.
authors.affiliation: Department of Internal Medicine and Specialistic Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cuzzocrea
authors.forename: Tiziana
authors.initials: T
authors.lastname: Genovese
authors.forename: Marco
authors.initials: M
authors.lastname: Failla
authors.forename: Graziella
authors.initials: G
authors.lastname: Vecchio
authors.forename: Mary
authors.initials: M
authors.lastname: Fruciano
authors.forename: Emanuela
authors.initials: E
authors.lastname: Mazzon
authors.forename: Rosanna
authors.initials: R
authors.lastname: Di Paola
authors.forename: Carmelo
authors.initials: C
authors.lastname: Muià
authors.forename: Cristina
authors.initials: C
authors.lastname: La Rosa
authors.forename: Nunzio
authors.initials: N
authors.lastname: Crimi
authors.forename: Enrico
authors.initials: E
authors.lastname: Rizzarelli
authors.forename: Carlo
authors.initials: C
authors.lastname: Vancheri
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001706:Biopsy; D001761:Bleomycin / Q000633:toxicity*; D002336:Carnosine / Q000494:pharmacology*; D007249:Inflammation; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D055370:Lung Injury; D008297:Male; D051379:Mice; D023421:Models, Animal; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000473:pathology*
chemical_list: D001761:Bleomycin; D002336:Carnosine